Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 881.

https://doi.org/10.1182/blood-2025-881

Published: 2025

Journal Articles

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Blood (2025) 146 (Supplement 1): 5225.

https://doi.org/10.1182/blood-2025-5225

Published: 2025

Journal Articles

Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo

Blood (2025) 146 (Supplement 1): 3455.

https://doi.org/10.1182/blood-2025-3455

Published: 2025

Journal Articles

Relationship between salvage strategy and outcomes in patients with CBF or NPM1-mutated AML and first molecular relapse

Blood (2025) 146 (Supplement 1): 347.

https://doi.org/10.1182/blood-2025-347

Published: 2025

Journal Articles

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.

Blood (2025) 146 (Supplement 1): 5567.

https://doi.org/10.1182/blood-2025-5567

Published: 2025

Journal Articles

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

Blood (2025) 146 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2025-1658

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 43.

https://doi.org/10.1182/blood-2025-43

Published: 2025

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Phuong T Vo, Brenda M. Sandmaier, Megan Othus, Naveed Ali, Eduardo Rodríguez-Arbolí, Corentin Orvain, Chris Davis, Ryan S. Basom, Rainer F. Storb, Roland B. Walter

Blood (2024) 144 (Supplement 1): 7314.

https://doi.org/10.1182/blood-2024-206221

Published: 2024

Journal Articles

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Blood (2024) 144 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2024-199055

Published: 2024

Journal Articles

Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Zi Yun Ng, Laurane Cottin, Damien Luque Paz, Corentin Orvain, Kamel Laribi, Jean-Christophe Ianotto, Eric Lippert, Alesia Khan, Daniel Lock, Valerie Ugo, Claire Harrison, Jennifer O'Sullivan

Blood (2024) 144 (Supplement 1): 485.

https://doi.org/10.1182/blood-2024-201326

Published: 2024

Journal Articles

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Blood (2024) 144 (Supplement 1): 478.

https://doi.org/10.1182/blood-2024-198903

Published: 2024

Journal Articles

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Blood (2024) 144 (Supplement 1): 58.

https://doi.org/10.1182/blood-2024-205592

Published: 2024

Journal Articles

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Mathilde Bastien, Maxime Jullien, Nicolas Vallet, Aline Schmidt, Tony Marchand, Amandine Le Bourgeois, Alice Garnier, Sophie Vantyghem, Aude-Marie Fourmont, Corentin Orvain, Marc Bernard, Thierry Guillaume, Jean-Baptiste Méar, Mathilde Hunault, Emmanuel Gyan, Pierre Peterlin, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 1531.

https://doi.org/10.1182/blood-2024-201589

Published: 2024

Journal Articles

Thromboembolism in Individuals with High-Oxygen-Affinity Hemoglobins - Systematic Review of the Literature

Marie Laloi, Agathe Gouband, Damien Luque-Paz, Marianne Schwarz, Aline Schmidt, Valerie Ugo, Hunault-Berger Mathilde, Loic Garcon, Corentin Orvain

Blood (2024) 144 (Supplement 1): 5226.

https://doi.org/10.1182/blood-2024-204536

Published: 2024

Journal Articles

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Blood (2024) 144 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2024-199110

Published: 2024

Journal Articles

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Blood (2024) 144 (Supplement 1): 731.

https://doi.org/10.1182/blood-2024-198614

Published: 2024

Journal Articles

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohan Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie Anne Hospital, Martin Carre, Emmanuelle Tavernier, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Eric Delabesse, Arnaud Pigneux, Hunault-Berger Mathilde, Christian Recher

Blood (2023) 142 (Supplement 1): 421.

https://doi.org/10.1182/blood-2023-184848

Published: 2023

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo

Relationship between salvage strategy and outcomes in patients with CBF or NPM1-mutated AML and first molecular relapse

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies.

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Thromboembolism in Individuals with High-Oxygen-Affinity Hemoglobins - Systematic Review of the Literature

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only